- Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
-
Nakagawa T, Kobayashi , Nishikawa , Yamada F, Asai S, Sameshima , Suzuki Y, Watanabe M, Hibi T
- KMID: 2465816
- Intest Res.
- 2019 Oct;17(4):504-515.
- doi: 10.5217/ir.2019.00030
BACKGROUND/AIMS: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. METHODS: Patients were prospectively... -
- CITED
-
- Close
- SHARE
-
- Close
